Acne Medication Market Projected to Reach $10,929 million by 2025 - Allergan, Nestle, Johnson & Johnson, Mayne Pharma, Mylan, Pfizer, GlaxoSmithKline, Sun, Teva, Valeant

Acne or acne vulgaris is a skin disease caused due to clogging of hair follicles with dead skin cells and oil from skin cells. This disease is characterized with pimples, blackheads, oily skin, and scarring. There are two types of acne-non-inflammatory and inflammatory acne, where the latter takes longer duration to heal and can cause permanent effects on the skin. Acne medications are either applied directly, which are present in formulations, or taken in the form of oral pills. These medications work by reducing inflammation and oil production. They also fight with bacteria finally preventing scarring. The common acne medications include retinoids, antibiotics, isotretinoin, benzoyl peroxide, and others.

The Global acne medication market was valued at $8,017 million in 2017, and is projected to reach $10,929 million by 2025 at a CAGR of 3.9% from 2018 to 2025. Increase in prevalence of acne diseases is the major factor that contributes toward the growth of the acne medication market. Moreover, other factors that fuel the market growth include unhealthy urban lifestyle, and presence of robust acne medications in pipeline. However, side-effects associated with the use of acne medications and presence of alternative treatment impede the market growth. Conversely, development of effective medications with lesser side effects and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market growth.


Get Sample PDF Copy at: https://www.premiummarketinsights.com/sample/AMR00013870

The Global acne medication market is segmented into therapeutic class, formulation, type, acne type, distribution channel, and region. Based on therapeutic class, the market is divided into retinoids, antibiotics, salicylic acid, benzoyl peroxide, and others. The retinoids segment is further classified into topical retinoid & combination retinoid and oral retinoid (isotretinoin). The antibiotics segment is further sub-segmented into topical antibiotics & combination antibiotics and oral antibiotics. Based on the formulation, the market is bifurcated into topical medication and oral medication. Based on type, the market is categorized into prescription medicine and over-the-counter (OTC) medicine. By acne type, the market is divided into non-inflammatory and inflammatory acne. The distribution channel covered in the study include grocery store, pharmacy & drug store, and e-commerce. Based on region, it is analyzed for across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global acne medication market with current trends and future estimations from 2017 to 2025 to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Get Complete Report at: https://www.premiummarketinsights.com/buy/AMR00013870

Name: Sameer Joshi
Email: sales@premiummarketinsights.com
Organization: Premium Market Insights
Phone: +1-646-491-9876

Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider.

This release was published on openPR.